A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
← catalyst calendarNCT06283966 · readout in 471 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
5,250estimated
Sites
921
Countries
Argentina, Australia, Austria +34
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-21 | actual | When the study began enrolling |
| Primary completion | 2027-12-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
- Drug: BGF MDI 320/14.4/9.6 μg
- Drug: GFF MDI 14.4/9.6 μg
Primary outcome
what the primary-completion date above is the date OFTime to first severe cardiac or COPD event
measured Up to 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed